AMSTERDAM, March 7, 2017 /PRNewswire/ -- Royal Philips
(NYSE: PHG, AEX: PHIA), today announced the expansion of its Dream
Family of products with the new DreamStation Advanced Therapies
platform designed to deliver optimal ventilation with minimal
mechanical intervention. Through these new offerings, DreamStation
now supports the most complex patient cases – those suffering with
sleep-disordered breathing and respiratory insufficiencies.
Worldwide, more than 100 million people have obstructive sleep
apneai,ii (OSA), with recent research
revealing that a significant percentage of these patients suffer
from more complex sleep-disordered breathingiii. Chronic
respiratory illness impacts a significant population worldwide,
with an estimated 65 million suffering from Chronic Obstructive
Pulmonary Disorder (COPD)iv , and even more suffering
from specific respiratory insufficiencies due to other chronic or
neuromuscular diseases, all requiring unique therapy. To address
the varying needs of these complex disorders, Philips designed the
DreamStation Advanced Therapies BiPAP autoSV and AVAPS devices.
Built on sophisticated, clinically-proven algorithms, BiPAP autoSV
aims to deliver optimal ventilation with minimal intervention so
patients experience comfortable, restful sleep, while BiPAP AVAPS
is designed to deliver effective and comfortable ventilation
therapy so patients can experience an improved quality of life.
"Treating patients with complex breathing disorders is not
always straightforward, and every patient has unique therapy needs
that can change night to night," said Mark
D'Angelo, Sleep Therapy Business Leader, Philips Sleep &
Respiratory Care. "In addition to medical support, they require
guidance and encouragement. With these updates to our Dream Family,
we can provide individualized support for a wider range patients
and empower clinicians to deliver the most efficient and best care
possible."
As with all Dream Family solutions, the DreamStation Advanced
Therapies are fully-integrated through Philips Encore Anywhere
patient management tool. This connectivity provides automated
support for the patient's specific and changing needs as well as
remote monitoring capabilities support for physicians, durable
medical equipment (DME) providers and caretakers to intervene when
needed to minimalize adverse events.
Currently available in in select markets including France, Australia and the
United States, the devices are expected to become available
globally by the end of 2017. The Philips Dream Family of products
launched in 2015 as a full suite of sleep solutions that connect
and support the patient, clinician and homecare provider to enhance
patient care and quality of life. With the launch of DreamStation
Advanced Therapies AVAPS device, Philips expands the Dream Family
to feature respiratory solutions. To learn more about the enhanced
DreamStation Platform, please visit:
http://www.usa.philips.com/healthcare/resources/landing/dreamstation-advanced-therapy-devices.html?origin=10_global_en_advancedtherapiesna_pr
For further information, please contact:
Meredith Amoroso
Senior Manager of Communications and Public Relations
Philips Sleep and Respiratory Care
Mobile: +1 724-584-8991
E-mail: meredith.amoroso@philips.com
About Royal
Philips
Royal Philips
(NYSE: PHG, AEX: PHIA) is a leading health technology company
focused on improving people's health and enabling better outcomes
across the health continuum from healthy living and prevention, to
diagnosis, treatment and home care. Philips leverages advanced
technology and deep clinical and consumer insights to deliver
integrated solutions. Headquartered in the Netherlands, the company is a leader in
diagnostic imaging, image-guided therapy, patient monitoring and
health informatics, as well as in consumer health and home care.
Philips' health technology portfolio generated 2015 sales of
EUR 16.8 billion and employs
approximately 70,000 employees with sales and services in more than
100 countries. News about Philips can be found
at www.philips.com/newscenter.
About Philips Sleep & Respiratory Care
Philips
Sleep & Respiratory Care is a global leader in the sleep and
respiratory care markets, offering solutions in sleep apnea
management, oxygen therapy, noninvasive ventilation and respiratory
drug delivery and has a long history of leading new innovation in
both devices and informatics solutions to help patients sleep and
breathe better.
i "Sleep Apnea: Epidemiology." Sleepdex.
http://www.sleepdex.org/epidemiologyapnea.htm. Accessed
December 2016.
ii Jean Bousquet and
Nikolai Khaltaev et. al. (2007). Global surveillance, prevention
and control of chronic respiratory diseases: a comprehensive
approach. Retrieved December 2016
from World Health Organization:
http://www.who.int/gard/publications/GARD%20Book%202007.pdf?ua=1
iii "The 3 Types of Sleep Apnea Explained:
Obstructive, Central and Mixed." Alaska Sleep Clinic.
http://www.alaskasleep.com/blog/types-of-sleep-apnea-explained-obstructive-central-mixed.
January 28, 2015.
iv "Burden of COPD." World Health Organization.
http://www.who.int/respiratory/copd/burden/en/. Accessed
December 2016.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/philips-expands-its-award-winning-dreamstation-platform-to-treat-patients-with-most-complex-sleep-and-breathing-needs-300418735.html
SOURCE Royal Philips